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Background aims. The aim of this study was to determine the optimal cell type for transplantation to protect against neonatal
hyperoxic lung injury. To this end, the in vitro and in vivo therapeutic efﬁcacies and paracrine potencies of human umbilical
cord bloodederived mesenchymal stromal cells (HUMs), human adipose tissueederived mesenchymal stromal cells
(HAMs) and human umbilical cord blood mononuclear cells (HMNs) were compared. Methods. Hyperoxic injury was
induced in vitro in A549 cells by challenge with H2O2. Alternatively, hyperoxic injury was induced in newborn Sprague-
Dawley rats in vivo by exposure to hyperoxia (90% oxygen) for 14 days. HUMs, HAMs or HMNs (5  105 cells) were
given intratracheally at postnatal day 5. Results. Hyperoxia-induced increases in in vitro cell death and in vivo impaired
alveolarization were signiﬁcantly attenuated in both the HUM and HAM groups but not in the HMN group. Hyperoxia
impaired angiogenesis, increased the cell death and pulmonary macrophages and elevated inﬂammatory cytokine levels.
These effects were signiﬁcantly decreased in the HUM group but not in the HAM or HMN groups. The levels of human
vascular endothelial growth factor and hepatocyte growth factor produced by donor cells were highest in HUM group,
followed by HAM group and then HMN group. Conclusions. HUMs exhibited the best therapeutic efﬁcacy and paracrine
potency than HAMs or HMNs in protecting against neonatal hyperoxic lung injury. These cell type-dependent variations in
therapeutic efﬁcacy might be associated or mediated with the paracrine potency of the transplanted donor cells.
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Despite recent improvements in neonatal intensive
care medicine [1], bronchopulmonary dysplasia
(BPD), a chronic lung disease in premature infants
that requires prolonged ventilatory support and oxy-
gen supplementation, remains a major cause of
mortality and long-term respiratory morbidity among
premature infants [2,3]. Few effective treatments are
available against BPD; therefore, the development of
a new therapeutic modality to improve the outcome of
this intractable disease is urgently needed.
Recently, the transplantation of various types of
stem/progenitor cells has shown potential in the pre-
vention and treatment of neonatal hyperoxic lung
injury [4e9]. Of the various types of stem/progenitor*These authors contributed equally to this study.
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http://dx.doi.org/10.1016/j.jcyt.2015.03.008cells, mesenchymal stromal cells (MSCs) are most
often used in cell transplantation studies using animal
models of BPD [6,9e15]. Although bone marrow
(BM) is the best characterized source of MSCs, the
practical use of BM is limited because of its highly
invasive acquisition process [16]. Adipose tissue
(AT), which can be harvested less invasively and in
larger quantities than BM, is one possible alternative
source of MSCs. However, the in vivo therapeutic
efﬁcacy of AT-derived MSCs in protecting against
hyperoxic lung injury has not yet been tested. Um-
bilical cord blood (UCB) is considered another
promising source for human MSCs because of its
ready availability and the lack of signiﬁcant ethical
concerns. However, a long expansion time is required
to obtain MSCs from UCB [17]. Thus, UCBg Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-
ark@samsung.com
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1026 S. Y. Ahn et al.mononuclear cells (MNCs), which contain high levels
of primitive, multipotent stem/progenitor cells [18],
might be a suitable alternative source for UCB-
derived MSCs in protecting against BPD [19].
To the best of our knowledge, the therapeutic ef-
ﬁcacies of various stem cells in protecting against
neonatal hyperoxic lung injury have not yet been
directly compared. The aim of the present study was
to determine the best cell type for protecting against
neonatal hyperoxic lung injury. To this end, the
therapeutic efﬁcacies of human UCB-derived MSCs,
AT-derived MSCs and UCB MNCs in protecting
against both in vitro and in vivo neonatal hyperoxic
lung injury were directly compared. We also evalu-
ated whether cell typeedependent variations in ther-
apeutic efﬁcacy were associated with or mediated by
paracrine potency by determining the amounts of
growth factors such as vascular endothelial growth
factor (VEGF) and hepatocyte growth factor (HGF)
produced by the transplanted donor cells.Methods
Cell preparation
Human UCB was collected from umbilical veins after
full-term newborn delivery. Informed consent was
obtained from all pregnant mothers before UCB
collection. From the single donor UCB, MSCs wereFigure 1. Comparison of the multi-lineage differentiation capacities and
“Fat” in the ﬁgure). (A) Differentiation potentials of UCB-MSCs and A
osteogenic (osteo), chondrogenic (chondro) and adipogenic (adipo) di
safranin O staining and enumeration of lipid vacuoles, respectively (sc
expression of various surface antigens on UCB MSCs and AT MSCs.isolated and expanded as previously described
[20,21]. The differentiation potentials and immuno-
phenotypic results of this process have also been pre-
viously described [11,20,22e24]. No changes in the
karyotype was observed until 11 passages of
UCB-MSCs (Supplementary Figure 1). Human
AT-derived MSCs were isolated from AT that had
been obtained from three adult females undergoing
elective liposuction procedures. All patients provided
informed consent. AT was isolated using collagenase
(type I, Sigma) [25]. Fluorescence-activated cell
sorter analysis revealed that both UCB-derived and
AT-derived MSCs were positive for typical MSC an-
tigens (CD73 and CD105) but negative for hemato-
poietic antigens (CD14, CD34 and CD45) by passage
6 (Figure 1A, Table I). To compare the differentiation
potentials of the human UCB-derived MSCs and the
AT-derived MSCs into mesodermal cells in vitro,
MSCs (passage 6) were cultured in induction media
for bone, cartilage and fat differentiation (Figure 1B).
Both UCB-derived MSCs and AT-derived MSCs
showed the potential to differentiate into bone, carti-
lage and fat, as evidenced by the resultant alkaline
phosphatase activity, safranin O staining and numbers
of lipid vacuoles, respectively. Human UCB-derived
MNCs were isolated by centrifugation of UCB on a
Ficoll-Hypaque gradient (density 1.077 g/cm3,
Sigma). The separated MNCs were washed and sus-
pended as previously described [24].immunophenotypes of MSCs obtained from UCB or AT (labeled
T-MSCs cultured under induction conditions. In each population,
fferentiation was examined by alkaline phosphatase live staining,
ale bar: 50 mm). (B) Flow cytometry analysis demonstrating the
Table I. Fluorescence-activated cell sorter analysis of MSCs.
Marker HLA-DR CD14 CD34 CD45 CD29 CD73 CD90 CD105
UCB MSC     þ þ þ þ
AT MSC     þ þ þ þ
HLA, human leukocyte antigen; , less than 5%; þ, more than 95%.
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A549 cells (human alveolar basal epithelial cells) were
purchased from the Korea Cell Line Bank. A549 cells
(5  103 cells/well) were seeded into 96-well plates in
100 mL of RPMI 1640 medium containing 10% fetal
bovine serum (Gibco) and cultured for 24 h at 37C.
To generate oxidative stress, cells were treated with
100 mmol/L H2O2 for 60 min as previously described
[26]. Then, H2O2-treated A549 cells were incubated
in complete medium (CM) alone, CM with 1  103
human UCB-derived MSCs, CM with 1  103 hu-
man AT-derived MSCs or CM with 1  103 human
UCB MNCs for 24 h. The resultant supernatants
were preserved at 70C until enzyme-linked
immunosorbent assay (ELISA) was performed. A
colorimetric MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium] assay (Dojindo Molecular
Technologies) was used to evaluate cell viability
according to the manufacturer’s protocol. Relative
viabilities were determined by normalizing to 0% (no
cells) and 100% (untreated cells) controls.Animal work
The Animal Care and Use Committee of Samsung
Biomedical Research Institute (Seoul, Korea)
approved all animal procedures in this study. This
study was also conducted in accordance with all
institutional and National Institutes of Health guide-
lines for laboratory animal care. Timed pregnant
Sprague-Dawley rats (Orient Co.) spontaneously
delivered newborn rat pups as previously described
[11]. Newborn rats were randomly allocated to ﬁve
experimental groups: normoxia control (NC) (n ¼
18), hyperoxia control (HC) (n ¼ 20), hyperoxia with
transplantation of human UCB-derived MSCs
(HUM) (n ¼ 22), hyperoxia with transplantation of
human AT-derived MSCs (HAM) (n ¼ 18) and
hyperoxia with transplantation of humanUCBMNCs
(HMN) (n ¼ 17). Normoxic rats were maintained in
normal room air, whereas hyperoxic rats were raised in
hyperoxic chambers (90% oxygen) from birth until
postnatal day (P) 14.Nursingmother rats were rotated
daily between hyperoxia and room-air litters to pre-
vent oxygen toxicity in the dams. On P5, 5  105
human UCB-derived MSCs, AT-derived MSCs or
UCB MNCs in 0.05 mL normal saline (0.9% NaCl)
were transplanted intratracheally [11e13]. Cell dosefor transplantation used in this study has been referred
to our previous study [12]. An equal volume of normal
saline was administered to the control groups in the
samemanner.OnP7 andP14, rat pupswere sacriﬁced
under deep pentobarbital anesthesia (60 mg/kg,
intraperitoneal), and lung tissue was harvested for
morphometric and biochemical analyses as previously
described [11e13].Morphometry
The degree of alveolarization was estimated using the
mean linear index (MLI) as previously described
[11,27e30]. A minimum of three sections per sam-
ple and a minimum of six ﬁelds per section were
evaluated randomly in a blinded manner.Terminal deoxynucleotidyl transferase dUTP nick end
labeling assay
Cell death in lung tissue was assessed using immu-
noﬂuorescent terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL) staining with an
in situ cell death detection kit (S7110 ApopTag,
Chemicon). TUNEL staining was performed ac-
cording to the manufacturer’s protocol as previously
described [11,27e30]. TUNEL-positive cells from
10 nonoverlapping ﬁelds (magniﬁcation 200) from
each condition were counted by investigators who
were blinded to the treatment groups.Immunohistochemistry
Immunoﬂuorescent staining was used to detect von
Willebrand factor (vWF), an indicator of angiogen-
esis, and ED-1, a marker of alveolar macrophages, in
deparafﬁnized 5-mm lung sections. Primary anti-
bodies were diluted as follows: anti-vWF, 1:200
(endothelial cell markers, rabbit polyclonals, Dako);
anti-CD68 and anti-ED-1, 1:100 (monocyte/
macrophage markers, mouse monoclonals, Milli-
pore). Secondary antibodies were diluted as follows:
ﬂuorescein isothiocyanateeconjugated anti-rabbit
immunoglobulin, 1:200 (green ﬂuorescence, Dako);
Alexa Fluor 488 conjugated anti-mouse immuno-
globulin, 1:100 (green ﬂuorescence, Molecular
Probes).
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imum of six ﬁelds per section were randomly chosen
for evaluation. The amount of vWF present in each
section was estimated by measuring the light signal
intensity of the immunoﬂuorescent staining with
Image J (U.S. National Institutes of Health).
Numbers of ED-1 positive cells were determined by
manual counting. These assessments were per-
formed by an investigator who was blinded to the
study groups.ELISA
Frozen lung tissue was homogenized in cold buffer
(50 mmol/L Tris-HCl, pH 7.4) supplemented with
1 mmol/L ethylenediaminetetraacetic acid, 1 mL
ethylene glycol tetraacetic acid, 1 mmol/L phenyl-
methanesulfonyl ﬂuoride or phenylmethylsulfonyl
ﬂuoride, 42 mmol/L KCl and 5 mmol/L MgCl2. To
remove cellular debris, homogenized lung tissue was
spun by centrifugation at 8000 g for 20 min at 4C.
The total protein contents in the supernatants were
then measured according to the Bradford method.
Supernatant levels of interleukin (IL)-1a, IL-1b and
IL-6 and tumor necrosis factor-a were measured
using the Multiplex MAP ELISA Kit (Millipore)
according to the manufacturer’s protocol. The
amounts of VEGF protein were determined using
human-speciﬁc and rat-speciﬁc VEGF Quantikine
ELISA kits (R&D Systems), and the levels of HGF
protein were measured using human-speciﬁc and rat-
speciﬁc HGF ELISA kits (Uscn Life Science) ac-
cording to the manufacturer’s protocols. The levels
of both human and rat VEGF and HGF were
measured in the lung tissue of rats into which human
donor cells had been transplanted. However, only
the levels of human VEGF and HGF were measured
in the supernatants of cocultured human A549 cells
and human donor cells.Statistical analyses
Data are expressed as mean  SD. Continuous
variables were compared between groups using one-
way analysis of variance with the least signiﬁcant
difference post hoc test. A P value of <0.05 was
considered signiﬁcant. SPSS version 18.0 (IBM) was
used for all analyses.Results
Mortality and body weight
The mortality rates of the hyperoxic groups were not
signiﬁcantly different (23%, 15%, 16% and 13% in
the HC, HUM, HAM and HMN groups,respectively). Regarding body weight growth after
P9, slower weight gain was observed in the hyperoxic
rats. Moreover, signiﬁcant improvement of this
growth retardation was observed in the HUM group
(P13 and P14) but not in the HAM or HMN groups
(data not shown).Protective effects of cell transplantation in vitro and
in vivo
In cultured A549 cells, H2O2 exposure signiﬁcantly
reduced cell survival. This oxidative stresseinduced
cell death was signiﬁcantly improved by co-treatment
of UCB-derived MSCs or AT-derived MSCs but not
by UCB-derived MNCs, with more attenuation in
the UCB-derived MSCs treated group compared
with the AT-derived MSCs treated group
(Figure 2A).
Representative photomicrographs showing the
histopathological differences and morphometric
analysis evidenced by MLI of the rat lungs in each
experimental group at P14 are shown in Figure 2B
and 2C. Impaired alveolar growth, as evidenced by
fewer alveoli, larger alveoli and heterogeneous alve-
olar size, was observed in the HC group compared
with the NC group. Signiﬁcantly higher MLI, which
is indicative of impaired alveolarization, observed in
the HC group compared with the NC group.
Moreover, hyperoxic lung injury represented by high
MLI was attenuated in both the HUM and HAM
groups but not in the HMN group, with more
attenuation in the HUM group than in the HAM
group (Figure 2B,C).
The signiﬁcant reduction in the amount of vWF
staining in the HC group compared with the NC
group, which is indicative of impaired angiogenesis,
was signiﬁcantly improved in the HUM group but
not in the HAM or HMN groups (Figure 3).TUNEL and ED-1 staining
The numbers of TUNEL-positive and ED-1 positive
cells were signiﬁcantly higher in the HC group
compared with the NC group (Figure 4). These
hyperoxia-induced increases in the numbers of
TUNEL-positive and ED-1 positive cells were
signiﬁcantly attenuated in the HUM group but not in
the HAM or HMN groups.Inﬂammatory cytokines
The levels of inﬂammatory cytokines such as IL-1a,
IL-1b, IL-6 and tumor necrosis factor-a were
signiﬁcantly elevated in rat lung tissue from the HC
group compared with the NC group (Figure 5). This
hyperoxia-induced increase in inﬂammatory cytokine
Figure 2. Cell viability in A549 cell culture with oxidative stress by 1 h H2O2 exposure in vitro and the degree of alveolarization of P14 rat lung
exposed to prolonged hyperoxia in vivo. (A) The cell viability was quantiﬁed with MTT assay after H2O2 treatment for 60 min in A549 lung
epithelial cell culture. (B)Degrees of alveolarization of the lung sections of P14 rat, as assessed by themean linear intercept. (C) Representative
optical microscopy photomicrographs of lung sections stained with hematoxylin and eosin (scale bar¼ 25 mm). Data are presented as means
SEM. *P < 0.05 compared with the normal control or NC group; #P < 0.05 compared with the H2O2 control or HC group;
FP < 0.05
compared with the H2O2+UCB-MSCs or HUM group;
JP < 0.05 compared with the H2O2þAT-MSC or HAM group.
Paracrine potency-dependent neonatal hyperoxic lung repair 1029production that was observed in the HC group was
generally signiﬁcantly attenuated in the HUM group
but not in the HAM or HMN groups. However, the
increase in IL-1b was signiﬁcantly attenuated in the
HUM, HAM and HMN groups, with higher atten-
uation observed in the HUM group than HMS or
HMN group.VEGF and HGF levels
Human VEGF and HGF levels were signiﬁcantly
reduced in the culture medium of A549 cells after
H2O2 exposure (Figure 6A). These H2O2-induced
decreases in the levels of VEGF and HGF weresigniﬁcantly recovered by co-treatment of UCB-
derived MSCs, AT-derived MSCs or UCB-derived
MNCs, with higher VEGF levels in the MSC-
treated groups compared with the MNC-treated
group, and a higher HGF level in the UCB-derived
MSC-treated group compared with the AT-derived
MSC- or UCB-derived MNC treated group.
In rat lung tissue, the levels of rat VEGF and HGF
were signiﬁcantly reduced in the HC group compared
with theNCgroup on both P7 and P14 (Figure 6D,F).
This hyperoxia-induced decrease in the level of rat
VEGF was signiﬁcantly attenuated in the HUM,
HAMandHMNgroups. This attenuation was greater
in the HUM and HAM groups compared with the
HMN group on P7 and in the HUM and HAM
Figure 3. Evidence of pulmonary angiogenesis in P14 rat pups. (A) Representative immunoﬂuorescence photomicrographs of vWF staining
in the lungs of P14 rats. vWF was labeled with the ﬂuorescent marker 5(6)-carboxy-ﬂuorescein diacetate N-succinimidyl ester (green),
whereas nuclei were labeled with 40,6-diamidino-2-phenylindole (blue; scale bars ¼ 50 mm). (B) Mean light signal intensity of vWF
immunoﬂuorescence staining per high power ﬁeld. Data are expressed as medians and 10th to 90th percentiles. *P < 0.05 compared with the
NC group; #P < 0.05 compared with the HC group; FP < 0.05 compared with the HUM group.
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VEGF that had been secreted from transplanted
donor cells was detected in both the HUM and HAM
groups on P7 but not on P14; human VEGF was not
detected in the HMN group on any day. The
hyperoxia-induced decrease in the level of rat HGF
was signiﬁcantly attenuated in the HUM group on
both P7 andP14 but not in theHAMorHMNgroups.
Human HGF was detected in the HUM group on P7
but not on P14; human HGF was not detected in the
HAM or HMN groups on any day.Discussion
Determining the most appropriate cell type and cell
source is crucial for future successful clinical trans-
lation of cell-based therapies into protection against
BPD. In addition to the ease with which they can be
obtained and the absence of any signiﬁcant ethical
concerns, UCB-derived MSCs also exhibit some
biological advantages compared with BM-derivedand AT-derived MSCs, such as low immunoge-
nicity and a higher proliferative capacity [31]. In the
present study, although AT-derived MSCs and UCB
MNCs provided partial and minimal protection,
respectively, against H2O2-induced cell death in vitro
and hyperoxic lung injury in vivo, human UCB-
derived MSCs best attenuated these damages. For
example, human UCB-derived MSCs were the most
effective in preventing impaired alveolarization and
angiogenesis, increased apoptosis and an inﬂamma-
tory response. We previously demonstrated the safety
and feasibility of transplantation of human UCB-
derived MSCs for treating BPD in a phase I clin-
ical trial [32]. Cumulatively, our ﬁndings suggest
that human UCB-derived MSCs are the most suit-
able cell source for future clinical use in protecting
against BPD.
Understanding the mechanism through which
transplantation of human UCB-derived MSCs,
compared with AT-derived MSCs or UCB MNCs,
best protects lung tissue against neonatal hyperoxic
Figure 4. TUNEL-positive cells and pulmonary macrophages in the distal lungs of P14 rat pups. (A) Representative photomicrographs of
TUNEL-positive cells and ED-1-positive cells in lung sections from P14 rats. TUNEL was labeled with ﬂuorescein isothiocyanateeconjugated
(green) and ED-1-positive alveolar macrophages were labeled with 5(6)-carboxy-ﬂuorescein diacetate N-succinimidyl ester (green). Cell nuclei
were labeled with 40,6-diamidino-2-phenylindole (blue) (scale bar; 25 mm). (B) Numbers of observed TUNEL-positive cells per high power
ﬁeld. (C) Numbers of ED-1-positive cells per high power ﬁeld. Data are presented as means  SEM andmedians and 10th to 90th percentiles.
*P < 0.05 compared with the NC group; #P < 0.05 compared with the HC group; FP < 0.05 compared with the HUM group.
Paracrine potency-dependent neonatal hyperoxic lung repair 1031lung injury is of particular interest. Previous studies
have shown that the protective effects of cell trans-
plantation are primarily mediated by paracrine ratherFigure 5. Measurements of the levels of lung inﬂammatory cytokines by E
a in the lungs of P14 rats are shown. Data are expressed as means  SE
with the HC group; FP < 0.05 compared with the HUM group.than regenerative mechanisms [11e13,15,33].
Growth factors secreted by donor cells, such as VEGF
and HGF, are known to be key paracrine mediatorsLISA. The levels of IL-1a, IL-1b, IL-6, and tumor necrosis factor-
M. *P < 0.05 compared with the NC group; #P < 0.05 compared
Figure 6. Expression levels of VEGF and hepatocyte growth factor HGF measured by ELISA in vitro and in vivo. Human A549 cells were
treated with H2O2 for 1 h to induce oxidative stress and co-cultured with human UCBMSCs, ATMSCs or MNC. The levels of (A) human
VEGF and (B) HGF were measured in the culture supernatant. The levels of human VEGF (C) and rat (host) VEGF (D) in the rat lung
exposed to prolonged hyperoxia were measured on P7 and P14. The levels of human HGF (E) and rat (host) HGF (F) in the rat lung were
also measured on P7 and P14. Data are expressed as means  SEM. *P < 0.05 compared with the normal control or NC group; #P < 0.05
compared with the H2O2 control or HC group;
FP < 0.05 compared with the H2O2þUCB-MSCs or HUM group; JP < 0.05 compared with
the HAM group.
1032 S. Y. Ahn et al.that protect against neonatal hyperoxic lung injuries
such as increased inﬂammation, oxidative stress
and apoptosis, and impaired angiogenesis and alveo-
larization [13,15,34]. In the present study, the pro-
tective effects of stem cell therapy against hyperoxic
lung injury positively correlated with the levels of
human VEGF and HGF produced by the trans-
planted donor cells. Thus, the best protection was
associated with the highest levels of paracrine growth
factors and was observed with the transplantation ofhuman UCB-derived MSCs, partial protection was
observed with moderate levels of paracrine growth
factors in the group receiving AT-derived MSCs and
minimal protection was observed with the lowest
levels of paracrine growth factors in the group
receiving UCB MNCs. Overall, these ﬁndings sug-
gest that the therapeutic efﬁcacy of stem cell therapy is
associated with or mediated by the paracrine potency
of the transplanted donor cells [35,36]. Moreover,
our data also suggest that the levels of paracrine
Paracrine potency-dependent neonatal hyperoxic lung repair 1033growth factors such as VEGF and HGF, which are
secreted by transplanted stem cells, are potential po-
tency biomarkers for the transplanted stem cells
[15,34,37].
In our previous study [15] and in the present
study, the upregulation of growth factors was primed
by the transplanted MSCs and then sustained by the
rat host tissue. Although the hyperoxia-induced de-
creases in the levels of VEGF and HGF were
signiﬁcantly attenuated in the present study, partic-
ularly by the transplantation of human UCB-derived
MSCs, the levels of VEGF and HGF were still
signiﬁcantly lower than those in the normoxia group
on both P7 and P14. Interestingly, overexpression of
VEGF and/or HGF in MSCs has been reported to
signiﬁcantly enhance the therapeutic efﬁcacy of stem
cellemediated neural and cardiac repair [38,39].
However, further studies are necessary to determine
whether overexpression of growth factors such as
VEGF and/or HGF enhances the beneﬁcial effects of
MSC transplantation in this BPD model.
In addition to human UCB-derived MSCs [31],
MSCs derived from other birth-associated tissue, such
as Wharton’s jelly and the umbilical cord, have also
exhibited higher cell proliferation and increased
secretion of chemokines, proinﬂammatory proteins
and growth factors compared with adult AT-derived
or BM-derived MSCs [40]. Donor age has been
shown to have a negative impact on MSC expansion
and differentiation potential, even when the stem cells
originate from the same source, that is, AT [41,42] or
BM [43]. These ﬁndings suggest that the improved
paracrine potency and therapeutic efﬁcacy observed in
this study of humanUCB-derivedMSCs in protecting
against neonatal hyperoxic lung injury compared with
AT-derivedMSCs or UCBMNCsmight be primarily
attributable to the donor age. Thus, this higher efﬁcacy
may be universal to MSCs derived from birth-
associated tissue. Overall, these ﬁndings suggest that
donor agemust be considered when aiming to develop
clinically successful stem cell therapies, and that fetal-
derived or newborn-derived MSCs might be the best
stem cell source for treating BPD [44].
Because of the long duration (4 weeks) of the
isolation, ex vivo expansion and characterization of
MSCs [17], the relatively short therapeutic time win-
dow for treating BPD could easily be missed [13,32].
Umbilical cord blood is a rich source of MNCs and
contains high levels of primitive, multipotent stem/
progenitor cells [18]. Because of the short timeframe
inwhich they can be obtained,UCBMNCsmight be a
good alternative cell source for MSCs for therapies
designed to protect against BPD [19].We found in the
present study that human UCB MNCs were not
protective against neonatal hyperoxic lung injury.However, because of to the heterogenous population
of MNCs, it should be considered that inevitable de-
viation at comparison of cell dosages between MSCs
and MNCs may be introduced.
In contrast to our results of the present study,
Monz et al. demonstrated that UCB-derived MNCs
signiﬁcantly attenuated hyperoxic lung injury in a
double hit mouse model of BPD [19]. The discrep-
ancies between our work and that of Monz et al.might
be attributable to differences in animal species, the
extent of hyperoxic exposure and the dose of MNCs.
Speciﬁcally, in the Monz et al. study, newborn mice
were exposed to 75% oxygen, and 2  105 cells were
given to mice weighing approximately 3 g; in contrast,
rats weremaintained in 90% oxygen, and 5 105 cells
were given to rat pups weighing approximately 8 g in
our study. Although UCB MNCs can easily be ob-
tained in a short period of time, it is difﬁcult to
quantify the exact amount of therapeutically effective
stem and/or progenitor cells within each batch of
MNCs.Moreover, stem cells for human trials must be
prepared in compliance with good manufacturing
practice, which requires a manufacturing license
[32,45]. Overall, these ﬁndings suggest that human
UCB MNCs might not be a suitable source for “off-
the shelf” clinical applications for treating BPD.
A previous report [31] displayed that trans-
plantation of bone marrowederived MNCs in the
sham normal mice did not induce functional or his-
tological changes in the lungs. Moreover, cord blood
T cells have experienced little or no antigen exposure
and thus present phenotypically and functionally
more naive characteristics compared with peripheral
bloodederived cells [25]. Monz et al. [19] also
proved improved histologic changes after allogenic
transplantation of human UCB-MNCs in the
neonatal mice model of lung injury. On the basis of
these ﬁndings, the concerns related with the immu-
nogenicity of UCB-derived MNCs may seem to be
less signiﬁcant in delineation of comparative efﬁcacy
between MNCs and MSCs transplantation, although
this still must be considered.
In summary, human UCB-derived MSCs were
the most effective cells in attenuating hyperoxic lung
injury in newborn rats, AT-derived MSCs were
partially effective and UCB MNCs were not effec-
tive. The cell type-dependent variations in thera-
peutic efﬁcacy were associated with or mediated by
the paracrine potencies, that is, the amounts of the
growth factors such as VEGF and HGF that were
produced by the transplanted donor cells. These
ﬁndings suggest that human UCB-derived MSCs
might be the optimal cell source for future
clinical use in protecting against BPD in premature
infants.
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